Jefferies initiated coverage on Amicus Therapeutics with a new price target
$FOLD
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies initiated coverage of Amicus Therapeutics with a rating of Buy and set a new price target of $18.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2024 | $17.00 → $12.00 | Overweight → Equal-Weight | Morgan Stanley |
| 9/6/2024 | $18.00 | Buy | Jefferies |
| 5/30/2024 | $18.00 | Overweight | Wells Fargo |
| 5/14/2024 | $13.00 | Neutral → Buy | Guggenheim |
| 12/19/2023 | $15.00 → $20.00 | Equal-Weight → Overweight | Morgan Stanley |
| 9/9/2022 | $14.00 | Equal-Weight | Morgan Stanley |
| 4/13/2022 | $11.00 | Neutral | Goldman |
| 2/24/2022 | $16.00 → $14.00 | Outperform | SVB Leerink |
Morgan Stanley downgraded Amicus Therapeutics from Overweight to Equal-Weight and set a new price target of $12.00 from $17.00 previously
Jefferies initiated coverage of Amicus Therapeutics with a rating of Buy and set a new price target of $18.00
Wells Fargo initiated coverage of Amicus Therapeutics with a rating of Overweight and set a new price target of $18.00
Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. "Th
PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus
Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President